First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).

Johanna C. Bendell, Johann S. de Bono, Mark N. Stein et al.|Journal of Clinical Oncology|2020

Cited by 20